scholarly journals Defining heterogeneity of human non-metastatic breast cancer tumor by identifying individual cell types using cellular and molecular markers

2012 ◽  
Vol 2 (1) ◽  
pp. 4
Author(s):  
Pravin D. Potdar ◽  
Sachin R. Chaugule
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Metastatic Breast Cancer ◽  
Individual Cell ◽  
Metastatic Breast ◽  
Cell Types ◽  
Cancer Tumor

Nab-Paclitaxel versus Docetaxel for the First-line Treatment of Metastatic Breast Cancer

2013 ◽  
Vol 09 (01) ◽  
pp. 45 ◽  
Author(s):  
William J Gradishar ◽  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Randomized Clinical Trials ◽  
Metastatic Breast ◽  
Sensory Neuropathy ◽  
Therapeutic Index ◽  
Tumor Xenograft ◽  
First Line ◽  
Treatment Regimens ◽  
Cancer Tumor

Taxane-based treatment regimens are standard first-line therapies for metastatic breast cancer (MBC). The clinical benefit of solvent-based taxanes, including solvent-based paclitaxel and docetaxel, in MBC has been established in large randomized clinical trials. Docetaxel has demonstrated greater efficacy versus solvent-based paclitaxel in at least one trial, but both solvent-based paclitaxel and docetaxel are associated with undesirable dose-limiting toxicities, including neutropenia, sensory neuropathy, and hypersensitivity reactions.nab-Paclitaxel, an albuminbound form of paclitaxel, was developed to improve the therapeutic index of taxane treatment. This review summarizes preclinical experiments and clinical data from MBC trials comparingnab-paclitaxel with docetaxel. In preclinical studies,nab-paclitaxel more effectively suppressed tumor growth than docetaxel (80 versus 29 % inhibition) in breast cancer tumor xenograft models and was associated with less toxicity. Clinical studies confirmed these findings and reported a better therapeutic index with nab-paclitaxel than docetaxel. As such, the clinical experience withnab-paclitaxel supports its role as an important advance in the treatment of MBC with taxane-based regimens.

Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer

2002 ◽  
Vol 20 (9) ◽  
pp. 2319-2326 ◽  
Author(s):  
Catherine Van Poznak ◽  
Lee Tan ◽  
Katherine S. Panageas ◽  
Crispinita D. Arroyo ◽  
Clifford Hudis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Metastatic Breast Cancer ◽  
Estrogen Receptors ◽  
Clinical Response ◽  
Performance Status ◽  
Single Agent ◽  
Progesterone Receptors ◽  
Metastatic Breast ◽  
Taxane Chemotherapy

PURPOSE: The taxanes affect tubulin polymerization and interfere with mitotic transition. A checkpoint blockade at the G1-S boundary would be expected to promote taxane-induced apoptotic cell death through a mechanism that may involve p27. Other proposed determinants of clinical taxane sensitivity/resistance include p53, members of the epidermal growth factor receptor (EGFR) superfamily (eg, HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study. PATIENTS AND METHODS: We performed immunohistochemistry (IHC) for estrogen receptors, progesterone receptors, HER2, EGFR, p53, and p27 on 144 breast tumor specimens from patients treated for metastatic breast cancer on a series of clinical trials of single-agent taxane chemotherapy for correlation with clinical response (complete or partial response). Patient characteristics that could influence response (ie, performance status, extent of disease, and prior therapy) were also examined. RESULTS: In univariate analysis, Karnofsky performance status ≥ 90% and no prior history of anthracycline therapy correlated with a good clinical response to single-agent taxane (P = .003 and P = .041, respectively). None of the IHC variables tested were predictive of clinical response to taxane therapy, although p27 negativity showed a trend toward significance (P = .075). Concordance between the polyclonal antibody with HercepTest (DAKO, Carpinteria, CA) and the monoclonal antibody CB-11 (BioGenex, San Ramon, CA) was noted (kappa = 0.943); however, neither univariate nor multivariate analysis demonstrated an association between HER2 status and response to taxane chemotherapy. CONCLUSION: The IHC biomarkers studied were not predictive of response to single-agent taxane chemotherapy in patients with metastatic breast cancer. Identification of molecular correlates of taxane response remains an important goal.

Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer

2020 ◽  
Author(s):  
Katarzyna Joanna Jerzak ◽  
Danielle N Desautels ◽  
Phillip S Blanchette ◽  
Jane Bayani ◽  
Sharon Nofech-Mozes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast

scholarly journals Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1492 ◽  
Author(s):  
Valeria Rolih ◽  
Jerri Caldeira ◽  
Elisabetta Bolli ◽  
Ahmad Salameh ◽  
Laura Conti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
De Novo ◽  
Metastatic Breast ◽  
Cell Types ◽  
Metastasis Formation ◽  
Poor Overall Survival ◽  
Novel Approach

Metastatic breast cancer (MBC) is the leading cause of cancer death in women due to recurrence and resistance to conventional therapies. Thus, MBC represents an important unmet clinical need for new treatments. In this paper we generated a virus-like particle (VLP)-based vaccine (AX09) to inhibit de novo metastasis formation and ultimately prolong the survival of patients with MBC. To this aim, we engineered the bacteriophage MS2 VLP to display an extracellular loop of xCT, a promising therapeutic target involved in tumor progression and metastasis formation. Elevated levels of this protein are observed in a high percentage of invasive mammary ductal tumors including triple negative breast cancer (TNBC) and correlate with poor overall survival. Moreover, xCT expression is restricted to only a few normal cell types. Here, we tested AX09 in several MBC mouse models and showed that it was well-tolerated and elicited a strong antibody response against xCT. This antibody-based response resulted in the inhibition of xCT’s function in vitro and reduced metastasis formation in vivo. Thus, AX09 represents a promising novel approach for MBC, and it is currently advancing to clinical development.

scholarly journals Correlation between p53 protein expression and other molecular markers influencing the metastatic breast cancer outcomes

The Breast ◽  
2011 ◽  
Vol 20 ◽  
pp. S24-S25
Author(s):  
Sigita Liutkauskienė ◽  
Elona Juozaitytė ◽  
Darius Pranys ◽  
Lina Poškienė ◽  
Kristina Jurėnienė ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Markers ◽  
Metastatic Breast Cancer ◽  
Protein Expression ◽  
P53 Protein ◽  
Metastatic Breast ◽  
Cancer Outcomes ◽  
P53 Protein Expression ◽  
Breast Cancer Outcomes

scholarly journals Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib

2021 ◽  
Vol 15 ◽  
pp. 117822342110374
Author(s):  
Caitlin Handy ◽  
Robert Wesolowski ◽  
Michelle Gillespie ◽  
Michael Lause ◽  
Sagar Sardesai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Hormone Receptor ◽  
Tumor Lysis Syndrome ◽  
Metastatic Breast ◽  
Gene Encoding ◽  
Tumor Lysis ◽  
Hormone Receptor Positive ◽  
Cancer Tumor ◽  
Life Threatening

Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA-mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies. Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib. Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications. Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.

Sign in / Sign up

Export Citation Format

Share Document